Form 4: Puma Biotechnology Executive Sells Shares Under 10b5-1 Plan

Douglas M. Hunt, Senior Vice President of Regulatory Affairs at Puma Biotechnology, sold 8,633 shares of common stock at an average price of $3.1517 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Douglas M. Hunt, a Senior Vice President at Puma Biotechnology, sold 8,633 shares of the company's common stock.
• The sale occurred on January 2, 2025.
• The shares were sold at a weighted average price of $3.1517.
• The sale was executed under a pre-existing 10b5-1 trading plan adopted on December 14, 2020.
• The price range for the sales was between $3.11 and $3.2101 per share.
• Following the transaction, Mr. Hunt directly owns 124,594 shares of Puma Biotechnology.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction under a pre-arranged trading plan, with no indication of positive or negative sentiment. It is a neutral event.

Industry Context

This is a routine filing related to insider trading activity. It is common for executives to use 10b5-1 plans to sell shares to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies to manage their personal finances and avoid potential insider trading issues.
• The reported sale is consistent with typical insider trading activity, where executives may periodically sell shares for personal financial reasons.
• Similar filings are regularly made by executives at comparable biotech companies such as Amgen, Gilead, and Biogen.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on shareholder sentiment, but is unlikely to significantly affect the company's stock price due to the pre-arranged nature of the sale.

Key Dates

Keywords

Puma Biotechnology, PBYI, insider trading, stock sale, Form 4, 10b5-1 plan, executive, Douglas M. Hunt, regulatory affairs